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, the study follows work earlier this year showing that fibroblast cells from mouse skin can be transformed into neurons 2 and heart muscle 3 . However, it is the first study to accomplish direct reprogramming with human cells, and the first to create progenitor cells -in this case for blood. "It takes us a step along the line to believing that you can produce anything from almost anything, " says Ian Wilmut, director of the Medical Research Council Centre for Regenerative Medicine in Edinburgh, UK, who was not involved in the study. Mickie Bhatia, a stem-cell researcher at McMaster University in Hamilton, Canada, and his colleagues infected skin cells with a virus that inserted the OCT4 gene, then they grew the cells in a soup of immune-system stimulating proteins called cytokines. The gene's product, the OCT4 protein, is one of a handful of factors used to transform fibroblasts into iPS cells, but Bhatia's team found no evidence that the blood progenitor cells they made went through an embryonic state. For instance, the cells did not cause mice to develop teratomas -tumours that are characteristic of pluripotent cells, making iPS cells less attractive as a therapeutic option. The progenitors did, however, produce all three classes of blood cells -white, red and platelets -all of which were functional. The red blood cells also produced the adult form of haemoglobin, whereas iPS-cell-derived blood cells make the fetal form. "This is the most encouraging result we've seen for using blood cells for cell-replacement therapy, " says Bhatia.
Converted cells aren't without their drawbacks, though. Unlike iPS and embryonic stem cells, they cannot easily multiply in the lab, so producing the large quantities needed for screening drugs, for example, could be difficult, says Wilmut. It is also too early to tell whether they will be as good as the real thing when inside a person, says George Daley, a stem-cell biologist at Children's Hospital Boston in Massachusetts. Transplanting the cells into humans is still years away, says Bhatia. "The clinical side is going to be a lot of work. " ■
